title: Chlamydia pneumoniae infection in preeclampsia.
abstract: OBJECTIVE
  The maternal syndrome of preeclampsia results from systemic endothelial activation by a number of factors that primarily derive from the intervillous space, so-called intervillous soup. Co-precipitants, such as innate immune activators, may lower the threshold to develop the maternal syndrome in preeclampsia. We examined whether, like atherosclerosis, preeclampsia is associated with infection with Chlamydia pneumoniae (C. pneumoniae).
  
  
  METHODS
  A case-control study was performed on 50 women with preeclampsia, 57 women with normal pregnancies at term, and 25 non-pregnant controls. Anti-C. pneumoniae antibodies were examined by enzyme-linked immunosorbent assay and C. pneumoniae genomic DNA (gDNA) loads were measured by real-time PCR. We also performed a data synthesis of the relationship between anti-C. pneumoniae seroprevalence and preeclampsia risk.
  
  
  RESULTS
  Neither the number of women with measurable copy numbers of C. pneumoniae gDNA, the anti-C. pneumoniae seroprevalence, nor antibody indices of IgG, IgM, or IgA to C. pneumonia varied between groups. However, when measurable, gDNA copy numbers of C. pneumoniae were increased in women with preeclampsia compared with the normal pregnant (p < 0.05) and non-pregnant controls (p < 0.05). For women with measurable C. pneumoniae gDNA, their copy numbers were correlated with anti-C. pneumoniae IgG concentrations (r2 = 0.49; p < 0.0001). Data synthesis reveals that anti-C. pneumoniae IgG seroprevalence is associated with preeclampsia risk.
  
  
  CONCLUSIONS
  Our data suggest an association between C. pneumoniae infection and preeclampsia. While not a uniform and singular precipitant of the maternal syndrome of preeclampsia, C. pneumoniae infection may be a co-precipitant with other components of the intervillous soup. Further investigations appear warranted.
authors.affiliation: Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada.
authors.forename: Fang
authors.initials: F
authors.lastname: Xie
authors.forename: Yuxiang
authors.initials: Y
authors.lastname: Hu
authors.forename: Laura A
authors.initials: LA
authors.lastname: Magee
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Money
authors.forename: David M
authors.initials: DM
authors.lastname: Patrick
authors.forename: Robert M
authors.initials: RM
authors.lastname: Brunham
authors.forename: Eva
authors.initials: E
authors.lastname: Thomas
authors.forename: Peter
authors.initials: P
authors.lastname: von Dadelszen
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial; D016022:Case-Control Studies; D023521:Chlamydophila Infections / Q000150:complications* / Q000276:immunology; D016993:Chlamydophila pneumoniae / Q000235:genetics* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D011225:Pre-Eclampsia / Q000276:immunology / Q000382:microbiology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000382:microbiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018709:Statistics, Nonparametric
chemical_list: D000907:Antibodies, Bacterial